Hange-shashin-to, a Chinese herbal (Kampo) medicine, is prepared from seven crude herbs, Pinelliae tuber, Scutellariae radix, Zingiberis rhizoma, Ginseng radix, Glycyrrhizae radix, Zizyphi fructus, and Coptidis rhizoma. This medicine has been used for the empirical treatment of acute and chronic gastroenteric catarrh, fermentative diarrhea, and acute gastroenteritis. Hange-shashin-to has the effects of regulating the lower as well as upper gastrointestinal tract, and the mechanisms of those pharmacological effects have been partially elucidated.
One of the gastrointestinal motility regulatory factors on those empirical effects has been assumed to be the induction of changes in the levels of peptides (somatostatin, motilin, and gastrin) in plasma. [8] [9] [10] [11] [12] On the gastroprotective function as a neural emergency system, sensory afferent neurons in the gastrointestinal mucosa regulate neuropeptides (calcitonin gene-related peptide (CGRP) and tachykinins (substance P, etc.)) levels and play various physiological roles. 13, 14) CGRP possesses several potent biological activities, including vasodilation, being the most powerful vasoactive substance described to date, and it increases mucosal blood flow. [15] [16] [17] CGRP is known to coexist with tachykinins, in the population of sensory neurons in man. 18) Substance P is widely distributed in the central and peripheral divisions of the nervous system and in the enteroendocrine cells of gut, 19) and it participates in the regulation of gastrointestinal motility and secretion, 20) the hypothalamo-pituitary-adrenal axis, 21) and the stimulation of salivation. 22) To determine whether the pharmacological effects of Hange-shashin-to and Rikkunshi-to on the gastrointestine are due to changes in gastrointestinal mucosa regulatory peptides levels, we compared the plasma CGRP-like immunoreactive substances (IS) and substance P-IS levels after the administration of these Kampo medicines and related herbs.
MATERIALS AND METHODS

Materials
Hange-shashin-to (EK-14, lot 011A), prepared as a 3.8 g dried powder extract of Pinelliae tuber (5.0 g), Scutellariae radix (2.5 g), Zingiberis rhizoma (2.5 g), Ginseng radix (2.5 g), Glycyrrhizae radix (2.5 g), Zizyphi fructus (2.5 g), and Coptidis rhizoma (1.0 g); and Rikkunshito (EK-43, lot 26L99), prepared as a 4.1-g dried powder extract of Ginseng radix (4.0 g), Atractylodis rhizoma (4.0 g), Hoelen (4.0 g), Pinelliae tuber (4.0 g), Aurantii nobilis pericarpium (2.0 g), Zizyphi fructus (2.0 g), Glycyrrhizae radix (1.0 g), and Zingiberis rhizoma (0.5 g), were kindly supplied by Kanebo (Tokyo, Japan). Zingiberis rhizoma was purchased from Sainokiyu (Osaka, Japan), and its extract contained 0.72 percent 6-gingerol as a bioactive compound. Pinelliae tuber extract were purchased from Nippon Funmatsu Yakuhin (Osaka, Japan). The placebo was the additive to of the EK-14, EK-43 formulation, Zingiberis rhizoma extract, and Pinelliae tuber extract alone.
Synthetic human CGRP and its fragment , and substance P were purchased from the Peptide Institute (Osaka, Japan). Antiserum to CGRP was purchased from Biogenesis (Poole, U.K.). Antiserum to substance P (RA-08-095) was purchased from Cambridge Research Biochemicals (Cambridge, U.K.). All other reagents were of reagent grade and commercially available.
Subjects Five healthy male volunteers without nasal allergy, aged 23-40 years, participated in this study. Each subject received information on the study's scientific purpose, which was approved by the Ethics Committee of Oita Medical University, and subsequently gave written informed consent. No subject received any medication for at least 1 month before the study. There were at least 3-month intervals between each study. This study was carried out in the time except February, March, and April.
Study Schedule Hange-shashin-to, Rikkunshi-to, Zingiberis rhizoma extract (2.5 g), Pinelliae tuber extract (5.0 g), or placebo at the same dose of 6.0 g (final weight with additive) was orally administered with water, and the five volunteers took the same test drug on the same day. All subjects ate lunch at 11:45-12:00, and the study was carried out from 14:00 until 18:00. Venous blood samples from a forearm vein were taken before and 20-240 min after the administration.
Preparation of Plasma Extract The blood was immediately placed in chilled tubes containing aprotinin (500 KIU/ml) and EDTA (1.2 mg/ml). After centrifugation, plasma was diluted with 4% acetic acid (pH 4.0) and loaded into Sep-Pak C18 cartridges (Millipore, MA, U.S.A.). The peptides in plasma were eluted with 70% acetonitrile in 0.5% acetic acid (pH 4.0) and lyophilized. The recovery of plasma CGRP-IS and substance P-IS was Ͼ90% with this extraction procedure.
Enzyme Immunoassay for CGRP and Substance P Peptide levels in plasma were measured using an enzyme immunoassay for CGRP-IS 23) and substance P-IS, 24) as previously described. Human CGRP (8-37) and substance P were conjugated with b-D-galactosidase (Boehringer Mannheim, Mannheim, Germany) with N-(e-maleimidocaproyloxy)-succinimide. 25) The assay was performed using a delayed addition method, and separation of bound and free antigen was performed on an anti-rabbit IgG (55641) (ICN Pharmaceuticals, OH, U.S.A.)-coated immunoplate. The fluorescence intensity of the fluorescent product 4-methylumbelliferon was measured with an MTP-100F microplate reader (Corona Electric, Ibaraki, Japan). The enzyme immunoassays for CGRP and substance P were sensitive to detection limits of 0.084 and 0.4 fmol/well.
Data Analysis Plasma CGRP-IS and substance P-IS levels are expressed as meanϮS.D. (pg/ml). Comparisons of mean values were made by analysis of variance and Dunnett's test. A value of pϽ0.05 was regarded as significant.
RESULTS
Effect of Hange-shashin-to on CGRP-IS and Substance P-IS Levels The plasma CGRP-IS level-time profile after the administration of Hange-shashin-to is shown in Fig. 1A . CGRP-IS levels of the placebo showed a decreasing tendency from 0 to 40 min. Hange-shashin-to caused significant increases in CGRP-IS at 40 and 60 min, compared with the response of the placebo, and enhanced the secretion of CGRP-IS.
Hange-shashin-to significantly increased substance P-IS levels between 60-180 min compared with the response of the placebo (Fig. 1B) . And the changes of substance P were almost twice as high levels as the placebo and showed durability compared with the CGRP-IS secretion.
Effect of Rikkunshi-to on CGRP-IS and Substance P- Figures 2A and 2B show plasma CGRP-IS and substance P-IS levels after the administration of Rikkunshito. Rikkunshi-to had no significant effect on plasma CGRP-IS and substance P-IS levels. Plasma peptide levels in both Rikkunshi-to and the placebo remained almost the same (CGRP-IS: about 20 pg/ml and substance P-IS: about 40 pg/ml) before and after the administration.
IS Levels
Effect of Herbs (Zingiberis rhizoma and Pinelliae tuber Extract) on CGRP-IS and Substance P-IS Levels
The plasma CGRP-IS levels after the administration of Zingiberis rhizoma extract are shown in Fig. 3A . Extract of Zingiberis rhizoma (2.5 g) caused significant increases in CGRP-IS at 40 min, and did not show a decreasing tendency from 0 to 40 min such as placebo. Figure 3B shows the effects of Zingiberis rhizoma extract on plasma substance P-IS levels. Zingiberis rhizoma extract caused significant increases of substance P-IS levels at 60 min compared with the response of the placebo. And the changes of substance P showed no durability.
Figures 4A and 4B show plasma CGRP-IS and substance P-IS levels in Pinelliae tuber. A 5.0 g Pinelliae tuber had no significant effect on plasma CGRP-IS and substance P-IS levels as well as Rikkunshi-to.
DISCUSSION
Recently, some gastrointestinal motility regulatory factors relative to the pharmacological effects of Kampo medicines has been assumed to be due to changes in regulatory peptides levels. Some abnormalities of gastrointestinal function are presumed to result from changes in hormone levels. Sensory afferent neurons in the gastrointestinal mucosa regulate neuropeptide levels, which play various physiological roles in gastroprotection.
CGRP is a powerful vasoactive substance, which is released from the sensory afferent nerve endings against gastric mucosal injury (acid and the other noxious chemicals such as capsaicin, ethanol, etc.) in the stomach. 13, 26, 27) CGRP increases gastric mucosal blood flow as a gastroprotective factor. 28, 29) In this study, Hange-shashin-to raised plasma CGRP-IS levels, but Rikkunshi-to had no effect. Hangeshashin-to might directly stimulate CGRP-containing nerves, or indirectly secrete CGRP accompanied by the stimulation of other secretion cells and some mechanisms.
The herbs contained in these Kampo medicines might have an effect on neuropeptides. Both Kampo medicines have Zingiberis rhizoma as a common ingredient, and its herb contains 6-gingerol and 6-shogaol as the main bioactive compound, both of which have vanilloid structures. Capsaicin, a vanilloid receptor agonist, stimulates capsaicin-sensitive afferent neurons, which release CGRP from their nerve endings.
14,30-32) Hange-shashin-to has a five-fold larger amount of Zingiberis rhizoma content than Rikkunshi-to. Thus, the amount of 6-gingerol and 6-shogaol of the Zingiberis rhizoma extract in Hange-shashin-to may be greater than that of Rikkunshi-to, in estimated amount. In previous reports, Zingiberis rhizoma extract and 6-shogaol increased intestinal blood flow, and CGRP (8-37), a CGRP receptor antagonist, abolished the reaction. 33) Furthermore, lafutidine, a histamine H 2 receptor antagonist, which has vanilloid structures and is structurally related to capsaicin, changed the levels of CGRP as well as Hange-shashin-to in human plasma. 34) In our study, Zingiberis rhizoma extract also significantly raised CGRP-IS levels, but the levels were different from changes in Hange-shashin-to in terms of degree of increase. The pattern of secretion in CGRP-IS after an administration of Zingiberis rhizoma extract showed little similarity to that of Hange-shashin-to at the increasing time. Due to this difference in degree in increase between Hange-shashin-to and Zingiberis rhizoma extract, another pharmacological mechanisms and/or herbs might also affect neuropeptide levels.
Substance P, tachykinins, coexists with CGRP in the sensory afferent neurons of the gastrointestinal mucosa, and is released with acetylcholine in response to depolarizing stimuli in the enteric nervous system. 35, 36) Hange-shashin-to raised substance P-IS levels after the administration. Those secretions of substance P showed delayed action and durability in comparison with changes of CGRP. The pattern of changes in Hange-shashin-to was partially found in Zingiberis rhizoma extract, but not in Rikkunshi-to. The effects in substance P on Kampo medicines and herbs resemble those of CGRP. Thus, these findings suggest that the secretion of CGRP and substance P might be related to similar mechanisms.
Substance P causes direct contractions of circular muscle in most regions of the mammalian intestine, stimulates small intestine motility, and controls human small intestinal motility. 37) This peptide influences the rate of gastric emptying, too. 38) Both Hange-shashin-to and Rikkunshi-to influence the rate of gastric emptying in man, and their pharmacological effects were proven in experiments.
1-7) Natural pungent substances, capsaicin and shogaol, have contractile effects on guinea pig ileum, and the effects were induced via the release of substance P from sensory nerve endings. 39, 40) The reasons why Rikkunshi-to had no effect on CGRP and substance P levels are unknown. Empirical effects of Rikkunshi-to were based on increasing blood flow in the stomach, accelerating gastric emptying, etc. As for Rikkunshi-to, a different pathway from Hange-shashin-to might work on gastroprotective functions. Hange-shashin-to has been clinically determined to be more effective than Rikkunshi-to for the treatment of hyper-functioning conditions. In our previous reports, we guessed that Hange-shashin-to and Rikkunshi-to might increase plasma somatostatin and motilin (partial) levels to improve gastrointestinal motor dysfunction. 8, 9) The changes in somatostatin levels caused by Hange-shashin-to were greater than by Rikkunshi-to. In the increasing time of somatostatin, Hange-shashin-to changed early, and its pattern of change was different from Rikkunshi-to. In this study, CGRP levels changed early, in coincidence with the changes in somatostatin after the administration of Hange-shashin-to. Different indications among Kampo medicines might be based on differences in their effects on gastroprotective neuropeptide levels, as well as on gastrointestinal motor regulatory peptides. The effects of Hange-shashin-to on neuropeptides were found in healthy subjects, so essentially, the effects of those Kampo medicines are necessary to investigate the neuropeptide levels on the pathological condition and at local gastric mucosa.
Hange-shashin-to raised plasma CGRP and substance P levels, while Rikkunshi-to had no effects. We hypothesized that the difference in pharmacological effect between Hangeshashin-to and Rikkunshi-to might be based on the effects of CGRP and substance P. And Zingiberis rhizoma might partially participate in both peptide changes.
